Fistulas are a frequent and serious complication of Crohn's disease. Most of the literature has been focused on perianal fistulas, which are by far the most frequent. The effectiveness of treatment with infliximab in fistulizing Crohn's disease was demonstrated in the ACCENT II trial. In that study, however, all patients had external fistulas, and the majority of those were perianal fistulas. The response to fistula treatment in other locations was not evaluated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2165/11586260-000000000-00000 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!